Summary:
In patients with type 2 diabetes mellitus (T2DM) suffering from diabetic foot (DF) or diabetic peripheral neuropathy (DPN), alprostadil intravenous injection (40 μg daily for 14–21 days, added to standard care) significantly improved clinical response rates and lipid metabolism compared to standard care alone without alprostadil, though it was associated with a low rate of mild adverse events (3.33%).
| PICO | Description |
|---|---|
| Population | Adult patients with type 2 diabetes mellitus diagnosed with either diabetic foot (DF) or diabetic peripheral neuropathy (DPN). |
| Intervention | Alprostadil intravenous injection (40 μg/day) administered for 14 to 21 days in addition to standard diabetes care. |
| Comparison | Standard care alone, including blood glucose control and symptomatic management, without alprostadil. |
| Outcome | The observation group had a significantly higher total efficacy rate (93.33% vs. 76.67%, P=0.011), greater improvements in lipid profiles (TC ↓1.24±0.32 mmol/L, TG ↓0.86±0.21 mmol/L, LDL-C ↓0.92±0.25 mmol/L, HDL-C ↑0.35±0.10 mmol/L), and a lower incidence of adverse events (3.33% vs. 18.83%, P=0.008). |
Clinical Context
Diabetic foot and diabetic peripheral neuropathy represent devastating microvascular complications that significantly impact quality of life and carry substantial morbidity risk including limb amputation. These complications share underlying pathophysiology involving endothelial dysfunction, impaired microcirculation, and tissue hypoxia exacerbated by the metabolic derangements of diabetes. Alprostadil, a synthetic prostaglandin E1 analog, has been used in various countries for peripheral vascular diseases due to its vasodilatory, antiplatelet, and cytoprotective properties. The medication promotes microcirculatory blood flow through vasodilation, inhibits platelet aggregation reducing thrombotic risk, and may provide direct neuroprotective effects. For diabetic microvascular complications where perfusion impairment contributes to tissue damage and impaired healing, alprostadil represents a pharmacological approach to improving local blood supply. This study evaluated whether adding intravenous alprostadil to standard diabetes care improves clinical outcomes in patients with established diabetic foot or peripheral neuropathy.
Clinical Pearls
- Alprostadil addition to standard care achieved a 93.33% clinical efficacy rate compared to 76.67% with standard care alone, representing a clinically meaningful 17 percentage point absolute improvement.
- Substantial improvements in lipid parameters occurred with alprostadil treatment, including reductions in total cholesterol, triglycerides, and LDL-cholesterol alongside HDL-cholesterol elevation.
- The alprostadil group paradoxically experienced fewer adverse events (3.33%) than the control group (18.83%), suggesting the treatment may have protective effects beyond the primary indication.
- The 14-21 day treatment duration represents an intensive but time-limited intervention course that could be incorporated into hospital-based or infusion center care pathways.
Practical Application
Clinicians managing patients with diabetic foot or peripheral neuropathy should consider alprostadil infusion as an adjunctive therapy, particularly in cases with significant microvascular component or inadequate response to standard wound care and glycemic optimization. The intravenous administration requirement necessitates either hospitalization or outpatient infusion center access, limiting applicability in some healthcare settings. Patient selection should prioritize those with evidence of perfusion impairment who might benefit most from vasodilatory therapy. The favorable safety profile observed, with lower adverse event rates than control, supports broader consideration of this intervention. However, clinicians should recognize that alprostadil addresses only one component of diabetic foot pathophysiology and must be combined with comprehensive wound care, infection management, offloading, and metabolic optimization.
Broader Evidence Context
Alprostadil has been studied extensively for peripheral arterial disease and has established use in several countries for diabetic microvascular complications, though evidence quality has been variable. Meta-analyses have suggested benefits for diabetic foot healing and neuropathy symptom improvement, though many included studies have methodological limitations. This controlled trial adds to the evidence base supporting alprostadil’s role in diabetic complications management. The lipid improvements observed align with known effects of prostaglandin E1 on hepatic lipid metabolism and may represent an additional benefit beyond direct vascular effects. International practice patterns vary considerably regarding alprostadil use in diabetes, with more routine application in Asian and European settings compared to North America.
Study Limitations
- The study combined diabetic foot and peripheral neuropathy patients, conditions with overlapping but distinct pathophysiology, potentially obscuring differential treatment effects.
- The definition of “clinical efficacy” and specific outcome measures were not detailed in the summary, limiting interpretation of the primary endpoint.
- Follow-up duration beyond the treatment period was not specified, leaving questions about durability of benefits.
- The lower adverse event rate in the treatment group is unusual and may reflect differences in baseline characteristics or reporting rather than true protective effects.
- Blinding was not mentioned, introducing potential for performance and detection bias in efficacy assessments.
Bottom Line
Intravenous alprostadil added to standard care significantly improves clinical response rates and lipid profiles in patients with diabetic foot or peripheral neuropathy with an acceptable safety profile. Clinicians should consider alprostadil infusion as adjunctive therapy for diabetic microvascular complications, particularly where perfusion impairment contributes to disease manifestations.
Source: Liu, Yidong, et al. “Effectiveness and safety of alprostadil injection in the treatment of patients with type 2 diabetes complications.” Read article here.
